Protective effects of breviscapine on myocardial hypertrophy and fibrosis induced by isoproterenol in rats

Chinese Pharmacological Bulletin

Volumn 21, Issue 12, 2005, Pages 1514-1517

  He, Wei ^a   Zeng, Fan Dian ^b  

^a GANNAN MEDICAL UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Breviscapine; Fibrosis; Isoproterenol; Myocardial hypertrophy

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANGIOTENSIN II; BREVISCAPINE; HYDROXYPROLINE; ISOPRENALINE; NITRIC OXIDE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DECAPITATION; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; NONHUMAN; RADIOIMMUNOASSAY; RAT; SPECTROPHOTOMETRY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 32344450295     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Zheng M , Han QD, Xiao RP. Distinct β-adrenergic receptor sub-type singaling in the heart and their pathophysiologoical relevance [J]. Acta Physiologica Sinica, 2004,56(1):1-15.
2. Stanton HC, Brenner G, Mayfield ED Jr. Studies on isoproterenol-induced cardiomegaly in rats[J]. Am Heart J, 1969,77(1):72-80.
3. Boluyt MO, Long X, Eschenhagen T et al. Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart [J]. Am J Physiol Heart Circ Physiol, 1995,269( 2 pt 2):H638-47.
4. Borges JC , Suva JA Jr, Gomes MA et al. Tonin in rat heart with experimental hypertrophy [J]. Am J Physiol Heart Circ Physiol, 2003,284(6):H2263-8.
5. Zhou JZ,Lei H,Chen YZ et al. Ventricular remodeling by scutellarein treatment in spontaneously hypertensive rats [J]. Chin Med J, 2002,115(3):375-7.
6. Ocaranza MP, Diaz-Araya G,Chiong M et al. Isopproterenol and angiotensin I -converting enzyme in lung, left ventricle and plasma during myocardial hypertrophy and fibrosis [J]. J Cardiovasc Pharmacol,2002,40(2):246.
7. Devereux RB. Therapeutic options in minimizing left ventricular hypertrophy[ J]. Am Mean J,2000,139(1 pt 2):s9-14.
8. Spinale FG, Holzgrefe HH, Mukherjee R et al. Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. effects on left ventricular and myocyte structure and function[J]. Circulation, 1995,92(3):562-78.
9. Nogano M,Higaki J,Nakamura F et al. Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy [J]. Wypertension, 1992,19(6 pt2):708-12.
10. Kim NN, Villegas S,Summerour SR et al. Regulation of cardiac fibroblast extracellular matrix production by bradykinin and nitric oxide[J]. J Mol Cell Cardiol, 1999,31(2):457-66.
11. Ritchie RH, Schiebinger RJ, LaPointe MC et al. Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide [J]. Am J Physiol Heart Circ Physiol, 1998,275( 4 pt 2):H1370-4.
12. Bledsoe G, Chao L, Chao J. Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats[ J]. Am J Physiol Heart Circ Physiol, 2003,285 (4):H1479-88.